First-Generation GLP-1
GLP-1 Receptor Agonist
Best For
Sustained weight management, metabolic health optimization, cardiovascular risk reduction
GLP-1
Body weight studied in the STEP 1 trial program
SELECT
Cardiovascular outcomes studied in the SELECT trial
68wk
Duration of landmark efficacy trials
How It Works
This first-generation GLP-1 is a long-acting GLP-1 receptor agonist that binds to incretin receptors on pancreatic beta cells and hypothalamic neurons. By activating GLP-1 receptors in the arcuate nucleus, it suppresses appetite signaling while simultaneously delaying gastric emptying — prolonging satiety after meals. The compound also improves peripheral insulin sensitivity by enhancing glucose-dependent insulin secretion and suppressing glucagon release, which collectively shift the body toward sustained fat oxidation.
Key Research Areas
Appetite Signaling
Studied for effects on caloric intake via central hypothalamic signaling
Metabolic Research
Body weight studied over 68 weeks in the STEP 1 trial program
Insulin Sensitivity
Lowers fasting glucose and HbA1c by enhancing glucose-dependent insulin release
Cardiovascular Research
Cardiovascular outcomes studied in the SELECT trial
Research Highlights
- Most-studied GLP-1 agonist with over 10,000 participants across STEP trials
- Demonstrated cardiovascular benefit independent of weight loss
Featured Research
Formulation Notes
Common concentrations referenced in published clinical studies:
[SM5]5mg[SM10]10mg[SM15]15mg[SM20]20mg[SM30]30mgCategory
GLP-1, GIP, and glucagon receptor agonists represent the most significant advance in metabolic medicine. These peptides ...
Explore Lean Body category →Educational Content. This compound profile is for informational purposes only. Not intended as medical advice, diagnosis, or treatment.
Related Compounds
Second-Generation GLP-1
Dual GIP/GLP-1 Agonist
- Superior to single-agent therapies in every trial
- Activates two incretin pathways for broader metabolic impact
Reference Codes
[TR20]20mg[TR40]40mgThird-Generation GLP-1
Triple GLP-1/GIP/Glucagon Agonist
- Broadest receptor pathway activation — 3 mechanisms at once
- Enhances daily energy expenditure and lean mass preservation
Reference Codes
[RT20]20mg[RT30]30mgAOD-9604
HGH Fragment 177-191
- Isolates the fat-loss mechanism of growth hormone without systemic side effects
- Granted GRAS status by the FDA in 2007 for oral anti-obesity applications
Reference Codes
[5AD]5mgEvidence reviewed: March 2026